Skip to main content
Navamedic logo

Navamedic — Investor Relations & Filings

Ticker · NAVA ISIN · NO0010205966 LEI · 529900LKVQOR2SRUJU71 OL Wholesale and retail trade
Open in API
Filings indexed 825 across all filing types
Latest filing 2024-04-30 Annual Report (ESEF)
Country NO Norway
Listing OL NAVA

About Navamedic

https://navamedic.com/

Navamedic is a pharmaceutical company that develops, produces, and commercializes a diverse portfolio of medicines and related health products. The company's offerings include specialty pharmaceuticals, branded generics, and consumer health items. Its product portfolio addresses various medical needs, with treatments for conditions such as obesity, Parkinson's disorder, and inborn errors of metabolism, in addition to antibiotics. Serving as a reliable supplier and distribution partner, Navamedic provides high-quality products to hospitals and pharmacies, with a strong presence in the Nordic region and the Netherlands. The company focuses on improving patient outcomes through innovations, including advancements in personalized treatment for Parkinson's care.

Recent filings

Filing Released Lang Actions
Navamedic ASA: Annual Report 2023
Annual Report (ESEF) Classification · 100% confidence FY 2023
2024-04-30 English
Navamedic ASA: Annual Report 2023
Annual Report Classification · 100% confidence The document is explicitly titled 'Annual report 2023' and contains comprehensive sections including a CEO comment, Directors' report, ESG report, consolidated financial statements, notes to the financial statements, and an auditor's report. It provides detailed financial performance data for the full fiscal year 2023, which aligns perfectly with the definition of a 10-K (Annual Report). FY 2023
2024-04-30 English
Navamedic ASA: Annual Report 2023
Report Publication Announcement Classification · 98% confidence The document explicitly states: "Navamedic ASA: Annual Report 2023" and "Navamedic ASA has today published its Annual Report for 2023 approved by the Board of Directors. Find enclosed the report in PDF..." Although the content is the Annual Report for 2023, the document itself is a very short announcement (1379 characters) whose primary function is to state that the Annual Report has been published and is enclosed/available elsewhere. According to Rule #2 (The 'MENU VS MEAL' Rule), a short announcement stating a report has been published should be classified as a Report Publication Announcement (RPA), not the full report (10-K).
2024-04-30 English
Navamedic 1. kvartal 2024: Vellykket produktlansering og jevn fremgang i driften
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive quarterly financial report for Navamedic ASA for Q1 2024. It contains detailed financial statements, including a consolidated profit and loss statement, balance sheet, and cash flow statement, along with management's analysis of business trends, operational progress, and outlook. It is not a short announcement or a certification, but a full interim report. Q1 2024
2024-04-30 English
Navamedic Q1 2024: Successful product launch and steady operational progress
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive quarterly financial report for Navamedic ASA for Q1 2024. It contains detailed financial statements, including a consolidated profit and loss statement, balance sheet, and cash flow statement, along with management's analysis of business trends, operational progress, and outlook. It is not a mere announcement or certification, but the substantive financial report itself, fitting the definition of an Interim/Quarterly Report. Q1 2024
2024-04-30 English
Navamedic 1. kvartal 2024: Vellykket produktlansering og jevn fremgang i driften
Earnings Release Classification · 100% confidence The document is a press release titled "Navamedic 1. kvartal 2024: Vellykket produktlansering og jevn fremgang i driften" (Navamedic Q1 2024: Successful product launch and steady progress in operations). It details key financial figures (revenue, Adjusted EBITDA, gross margin) for the first quarter of 2024, discusses product performance (Eroxon, Modifast, Mysimba), and outlines future outlook. This structure—providing key financial highlights for a specific reporting period (Q1 2024) immediately following the period close—is characteristic of an Earnings Release (ER). It is not the comprehensive Annual Report (10-K) or the detailed Interim Report (IR), but rather the initial announcement of results. The text also mentions that a presentation will follow, confirming this is the initial release. Q1 2024
2024-04-30 Norwegian

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.